GlassScriptPhysician profile
Fereshteh Azad
NPI 1033738497
$2,022.25
in general payments reported to CMS, 2019-2025
10 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $609 · 2023: $546 · 2024: $373 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $611.49 | 2022-2024 | Clareon, Centurion |
| Amgen INC. | $293.61 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $254.93 | 2023 | Omni Surgical System |
| Abbvie INC. | $225.77 | 2022-2023 | Durysta |
| Genentech USA, INC. | $145.13 | 2022 | |
| Kerecis Limited | $128.53 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Bausch & Lomb Americas INC. | $107.91 | 2025 | Envista Mx60 Iol |
| Stryker Corporation | $48.64 | 2025 | Core |
| Tarsus Pharmaceuticals, INC. | $25.26 | 2025 | Xdemvy |
| Cumberland Pharmaceuticals, INC. | $16.16 | 2023 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fereshteh Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.